H
59.61
-1.48 (-2.42%)
前收盘价格 | 61.09 |
收盘价格 | 61.08 |
成交量 | 1,464,051 |
平均成交量 (3个月) | 1,383,748 |
市值 | 7,584,001,536 |
市盈率 (P/E TTM) | 19.74 |
预期市盈率 (P/E Forward) | 10.91 |
价格/销量 (P/S) | 6.52 |
股市价格/股市净资产 (P/B) | 13.36 |
52周波幅 | |
利润日期 | 31 Oct 2024 |
营业毛利率 | 41.43% |
营业利益率 (TTM) | 56.26% |
稀释每股收益 (EPS TTM) | 3.02 |
季度收入增长率 (YOY) | 34.30% |
季度盈利增长率 (YOY) | 67.40% |
总债务/股东权益 (D/E MRQ) | 339.05% |
流动比率 (MRQ) | 10.36 |
营业现金流 (OCF TTM) | 402.95 M |
杠杆自由现金流 (LFCF TTM) | 339.29 M |
资产报酬率 (ROA TTM) | 14.87% |
股东权益报酬率 (ROE TTM) | 111.83% |
市场趋势
短期 | 中期 | ||
行业 | Biotechnology (US) | 混合的 | 混合的 |
Biotechnology (全球的) | 混合的 | 混合的 | |
股票 | Halozyme Therapeutics, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
1.1
分析师共识 | -0.5 |
内部交易活动 | NA |
价格波动 | -0.5 |
技术平均移动指标 | 1.5 |
技术振荡指标 | 4.0 |
平均 | 1.13 |
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. |
|
部门 | Healthcare |
行业 | Biotechnology |
投资方式 | Small Growth |
内部持股比例 | 1.06% |
机构持股比例 | 100.80% |
52周波幅 | ||
目标价格波幅 | ||
高 | 73.00 (JMP Securities, 22.46%) | 购买 |
中 | 63.50 (6.53%) | |
低 | 53.00 (Piper Sandler, -11.09%) | 保留 |
平均值 | 63.25 (6.11%) | |
总计 | 2 购买, 2 保留 | |
平均价格@调整类型 | 54.22 |
公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
---|---|---|---|---|
Wells Fargo | 13 Jan 2025 | 57.00 (-4.38%) | 保留 | 54.14 |
HC Wainwright & Co. | 10 Jan 2025 | 70.00 (17.43%) | 购买 | 52.80 |
30 Dec 2024 | 68.00 (14.07%) | 购买 | 47.99 | |
Piper Sandler | 10 Jan 2025 | 53.00 (-11.09%) | 保留 | 52.80 |
04 Nov 2024 | 52.00 (-12.77%) | 保留 | 58.47 | |
JMP Securities | 01 Nov 2024 | 73.00 (22.46%) | 购买 | 57.15 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合